Nanologica secures SEK 110.5 million in a rights issue backed by Flerie Invest and Ardena to fund a strategic shift toward North American and European markets under new CEO Mark Quick.
Nanologica is executing a rights issue of approximately SEK 110.5 million to fund a strategic shift toward North American and European markets. The capital raise is accompanied by a significant management overhaul, including the appointment of Mark Quick as CEO, and is intended to provide sufficient runway to reach positive cash flow.
The proceeds are intended to finance the company until it achieves positive cash flow and to accelerate commercial investments in North America and Europe.
At full subscription including the oversubscription option and guarantee compensation, the maximum dilution effect is approximately 69.6%.
Flerie Invest AB, as the principal owner of Nanologica, is providing a subscription commitment of SEK 20.0 million to the rights issue. This commitment signals strong institutional support for Nanologica's new strategic direction and management team.
Flerie Invest AB is the principal owner of Nanologica and has committed to subscribing for SEK 20.0 million in the rights issue.
Ardena Gent NV has subscribed SEK 7.2 million and provided guarantee commitments, signaling continued partnership and confidence in Nanologica.
Nanologica AB has announced a SEK 110.5 million rights issue to accelerate commercial growth in North America and Europe. The capital raise, supported by principal owner Flerie Invest and partner Ardena, coincides with a management overhaul, including the appointment of Mark Quick as CEO. The company aims to reach positive cash flow through this strategic pivot and intensified market processing.
The company is raising capital to fund a strategic shift toward North American and European markets, aiming to accelerate commercial growth and reach positive cash flow.
Key supporters include principal owner Flerie Invest, partner Ardena Gent NV, and Chairman Thomas Eldered, alongside Sterling Pharma Solutions.